|By Marketwired .||
|July 8, 2014 05:10 PM EDT||
MINNEAPOLIS, MINNESOTA -- (Marketwired) -- 07/08/14 -- DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company focused on the treatment of diabetes and its complications, today announced a grant of 150,000 stock options to Richard Pilnik, the Company's newly appointed Chairman of the Board. The options were awarded in accordance with the Stock Option Plan at an exercise price of CAD $0.69 and a term of 10 years. The options are subject to acceptance by the TSX Venture Exchange.
DiaMedica Inc. is a publicly traded (TSX VENTURE: DMA) clinical stage biopharmaceutical company focused on the discovery and development of novel therapies to treat diabetes and the complications associated with diabetes. DiaMedica's lead clinical stage product, DM199, is a recombinant human protein known as rhKLK1 that represents a novel approach to treating diabetes and associated complications. DiaMedica is also developing a novel monoclonal antibody, DM204 for the treatment of Type 2 diabetes, which is in preclinical development.
The Company is listed on the TSX Venture Exchange in Canada under the trading symbol 'DMA'.
The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica's expectations, including the intended use of the net proceeds of the Offering, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in DiaMedica's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. DiaMedica undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events, unless required by law. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the contents of this press release.
Chief Financial Officer
May. 28, 2016 09:00 PM EDT Reads: 2,552
May. 28, 2016 07:00 PM EDT Reads: 1,252
May. 28, 2016 07:00 PM EDT Reads: 1,954
May. 28, 2016 07:00 PM EDT Reads: 3,598
May. 28, 2016 06:45 PM EDT Reads: 2,863
May. 28, 2016 06:45 PM EDT Reads: 2,002
May. 28, 2016 04:30 PM EDT Reads: 909
May. 28, 2016 04:00 PM EDT Reads: 1,681
May. 28, 2016 03:45 PM EDT Reads: 2,541
May. 28, 2016 03:30 PM EDT Reads: 2,022
May. 28, 2016 02:00 PM EDT Reads: 646
May. 28, 2016 02:00 PM EDT Reads: 2,927
May. 28, 2016 02:00 PM EDT Reads: 1,371
May. 28, 2016 01:00 PM EDT Reads: 2,345
SYS-CON Events announced today the Docker Meets Kubernetes – Intro into the Kubernetes World, being held June 9, 2016, in conjunction with 18th Cloud Expo | @ThingsExpo, at the Javits Center in New York, NY. Register for 'Docker Meets Kubernetes Workshop' Here! This workshop led by Sebastian Scheele, co-founder of Loodse, introduces participants to Kubernetes (container orchestration). Through a combination of instructor-led presentations, demonstrations, and hands-on labs, participants learn ...
May. 28, 2016 01:00 PM EDT Reads: 2,003